At the beginning of 2022, exactly 30 years have passed since the establishment of diplomatic relations between the Islamic Republic of Iran and the Republic of Kazakhstan. Since the establishment of diplomatic relations, more than $140 million of Iranian investments have already been attracted to the economy of Kazakhstan.
In February of this year, the 17th meeting of the Kazakh-Iranian Intergovernmental Commission was held in Tehran under the Deputy Prime Minister co-chairmanship of Kazakhstan - Minister of Trade and Integration Bakhyt Sultanov and Minister of Agriculture of Iran Seyed Javad Sadati Nejad, during which it was proposed to create a Kazakh–Iranian Business Council, which will allow building a dialogue between the business of the two countries, bypassing intergovernmental processes.
As part of the work of this commission Single Distributor visited a number of the largest pharmaceutical production sites in Iran, such as CinnaGen Co., Barkat Pharmaceutical Group and Saadat Co. There was also a meeting with the Iran Food and Drug Administration (IFDA), a state institution whose function is to regulate and register medicines, food, cosmetics, medical products, food additives, herbal supply chain management of medicines and MD.
In order to further develop cooperation with the pharmaceutical industry of Iran, on May 24, 2022, SK-Pharmacy LLP Single Distributor held an online meeting with representatives of the pharmaceutical company Barkat Pharmaceutical Group.
Barkat Pharmaceutical Group is one of the largest companies in Iran and ranks 2nd in the ranking of local pharmaceutical manufacturers.
The meeting was attended by Dr. Naeli, Advisor to the Director General for International Cooperation, and Dr. Porsa, Director General for Export, as well as Dr. Saidi, Commercial Manager of the company.
During the meeting Single Distributor presented the investment opportunities of the industry and the conditions of state benefits and preferences, as well as the opportunities of the Kazakh pharmaceutical market, its export potential and development prospects.
It was particularly noted that the localization of production at domestic production sites of original drugs with high added value, the creation of D centers and the implementation of the cluster initiative play a huge role in the development of domestic production.
It should be noted that pharmaceutical companies in Iran are among the most developed in the Middle East and North Africa region with a great potential for their own developments and the Kazakh side highlighted the great potential of economic cooperation between the two countries, announced the possibilities of increasing bilateral cooperation in the field of pharmaceutical production.
Following the meeting, the parties agreed on the need to work out the transfer of Iranian production technologies to the sites of Kazakhstani pharmaceutical manufacturers, their deep localization in the territory of the Republic of Kazakhstan, as well as cooperation in the development of new drugs and the development of R&D centers.
Also, the Iranian side was invited to continue discussing issues on further development of cooperation in the pharmaceutical industry within the framework of the upcoming exhibition of Iranian manufacturers, which is scheduled to be held in early June this year in Almaty.
Reference:
Pharmaceutical groupBarkat Pharmaceutical Group was founded in 2010. The company provides services in cooperation between scientific institutions and medical scientists around the world. It supplies 14 percent of all essential medicines to the country through its 25 subsidiaries.
Компания производит 700 видов продукции в фармацевтическом секторе и предлагает их собственными силами. Вклад в развитие социальной справедливости и повышение доступности для бедных людей современных товаров для здоровья за счет производства лекарств по доступным ценам и активного присутствие на региональных и глобальных рынках, особенно в исламских странах, входит в число целей компании.
The company produces 700 types of products in the pharmaceutical sector and offers them on its own. Contributing to the development of social justice and increasing the availability of modern health products for poor people through the production of medicines at affordable prices and an active presence in regional and global markets, especially in Islamic countries, is among the company's goals.
It was also created through the construction of advanced pharmaceutical plants called Barkat Pharmaceutical Town.
Barkat Group complies with all generally accepted pharmaceutical standards, such as FDA , ВОЗ , EMEA. The main activities are Cell therapy, the production of "peptide preparations", research, development and transformation of medicinal plants, Museum of Iranian-Islamic Medicine creation, as well as Solid and semi-solid groups projects.
On December 4, 2016, the company was registered as the 506th company on the Tehran Stock Exchange after receiving financing in the amount of 340 billion rials.
.png)
.jpeg)